A detailed history of Polymer Capital Management (Us) LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Polymer Capital Management (Us) LLC holds 15,230 shares of NTLA stock, worth $122,906. This represents 0.03% of its overall portfolio holdings.

Number of Shares
15,230
Holding current value
$122,906
% of portfolio
0.03%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

BUY
$7.11 - $12.8 $108,285 - $194,944
15,230 New
15,230 $108 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $613M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Polymer Capital Management (Us) LLC Portfolio

Follow Polymer Capital Management (Us) LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Polymer Capital Management (Us) LLC, based on Form 13F filings with the SEC.

News

Stay updated on Polymer Capital Management (Us) LLC with notifications on news.